metaEvidence - overview


			deaths (OS)
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pembrolizumab plus placebo
	pembrolizumab plus ipilimumab vs. pembrolizumab plus placebo	1
versus pemetrexed plus platin
	nivolumab plus ipilimumab vs. pemetrexed plus platin	1
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3
	cemiplimab vs. Standard of Care (SoC)	1
	durvalumab alone vs. Standard of Care (SoC)	1
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1
	nivolumab alone vs. Standard of Care (SoC)	2
	pembrolizumab alone vs. Standard of Care (SoC)	4